Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib PK in Hepatic Impairment
NCT03722823Phase 1Completed
- Sponsor
- Seagen Inc.
- Start
- Oct 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tucatinib in HER2-positive breast cancer and colorectal cancer (CRC) (4 arms), sponsored by Seagen Inc. Primary endpoints: Maximum observed concentration up to 48 hours, Time of maximum observed concentration up to 48 hours and 2 more. Started Oct 2018; status: completed.
02
Drugs
tucatinib
03
Conditions
HER2-positive breast cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03722823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03722823.